RAPP Rapport Therapeutics, Inc.
Q3 2025 10-Q
Rapport Therapeutics, Inc. (RAPP) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New clinical hold risk on RAP-219 diabetic peripheral neuropathic pain trial triggered by FDA request for protocol amendments in Q4 2024
- • Updated financial risk: net losses increased to $77.7M for nine months ended Sept 2025 from $58.3M in prior year, cash $513M funding through H2 2029
Get deeper insights on Rapport Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.